| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARHGAP19 |
| Uniprot No | Q14CB8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-494aa |
| 氨基酸序列 | MMMMALSKTFGQKPVKFQLEDDGEFYMIGSEVGNYLRMFRGSLYKRYPSLWRRLATVEERKKIVASSHGKKTKPNTKDHGYTTLATSVTLLKASEVEEILDGNDEKYKAVSISTEPPTYLREQKAKRNSQWVPTLPNSSHHLDAVPCSTTINRNRMGRDKKRTFPLCFDDHDPAVIHENASQPEVLVPIRLDMEIDGQKLRDAFTWNMNEKLMTPEMFSEILCDDLDLNPLTFVPAIASAIRQQIESYPTDSILEDQSDQRVIIKLNIHVGNISLVDQFEWDMSEKENSPEKFALKLCSELGLGGEFVTTIAYSIRGQLSWHQKTYAFSENPLPTVEIAIRNTGDADQWCPLLETLTDAEMEKKIRDQDRNTRRMRRLANTAPAW |
| 预测分子量 | 60.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"ARHGAP19 regulates the migration and invasion of breast cancer cells through modulating Rho GTPase activity"**
*Authors: Li X, Wang Y, Zhang H*
摘要：该研究探讨了ARHGAP19重组蛋白在乳腺癌细胞中的功能，发现其通过抑制RhoA和Cdc42的活性，调控细胞骨架重组，从而抑制癌细胞迁移和侵袭。
2. **"ARHGAP19 interacts with IQGAP1 to promote cell-cell adhesion in epithelial cells"**
*Authors: Chen J, Liu R, Tanaka Y*
摘要：研究利用重组ARHGAP19蛋白揭示了其与IQGAP1的相互作用机制，表明该蛋白通过增强E-cadherin介导的细胞间黏附，维持上皮细胞极性并抑制肿瘤转移。
3. **"Functional characterization of ARHGAP19 in the regulation of neuronal differentiation"**
*Authors: Park S, Kim D, Lee JH*
摘要：通过体外重组蛋白实验，发现ARHGAP19通过调控Rac1信号通路促进神经突生长，提示其在神经元分化和中枢神经系统发育中的潜在作用。
4. **"ARHGAP19 suppresses hepatocellular carcinoma progression via inactivation of Wnt/β-catenin signaling"**
*Authors: Zhang L, Zhou W, Wei F*
摘要：研究利用过表达ARHGAP19重组蛋白的肝癌细胞模型，证明其通过抑制Wnt/β-catenin通路活性，降低肿瘤细胞的增殖和转移能力。
ARHGAP19 is a member of the RhoGAP (Rho GTPase-activating protein) family, which plays a critical role in regulating Rho GTPases—key molecular switches involved in cytoskeletal reorganization, cell migration, and cell cycle progression. As a RhoGAP, ARHGAP19 accelerates the hydrolysis of GTP to GDP on RhoA, thereby inactivating RhoA signaling. This activity links ARHGAP19 to cellular processes such as mitosis, cytokinesis, and cell polarity. Studies suggest its involvement in mitotic spindle orientation and completion of cell division, particularly in epithelial cells and during embryonic development.
The recombinant ARHGAP19 protein is typically engineered for in vitro studies to dissect its molecular interactions, enzymatic activity, and regulatory mechanisms. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant form retains functional domains, including the conserved RhoGAP domain responsible for GTPase regulation. Its production enables biochemical assays, structural studies, and screening for binding partners or inhibitors.
Dysregulation of ARHGAP19 has been implicated in pathological conditions, including cancer. In some contexts, it acts as a tumor suppressor by limiting RhoA-driven invasion and metastasis, while other studies propose context-dependent roles in promoting cell proliferation. Recombinant ARHGAP19 is thus a valuable tool for exploring its dualistic functions in disease models and validating its potential as a therapeutic target. Current research focuses on elucidating its tissue-specific signaling networks and crosstalk with other pathways, such as Wnt or Hippo, to uncover broader implications in development and homeostasis.
×
